$7900 | Single User
$20500 | Global License

Therapy Trends: Alzheimer's Disease - Breaking new ground in disease modification
[Published by FirstWord Pharma]

Published by FirstWord Pharma: 01 Dec 2012 | 16 | In Stock
Related Topics: Lilly , Pfizer

Introduction

Introduction


In 2012, the Alzheimer’s disease (AD) market was dealt a huge blow following negative results from pivotal Phase III trials of Pfizer and J&J’s bapineuzumab and the intravenous formulation of the drug was discontinued. Expectations for beta-amyloid theory were low following this failure; however results from Eli Lilly’s solanezumab have offered a glimmer of hope for the AD community. Although missing its primary endpoints, pooled analysis of solanezumab data in mild patients showed a statistical significant slowdown of cognitive decline.


With novel therapies slowly emerging from the pipeline, such as beta secretase and tau therapies, and positive research into biomarkers to aid early AD diagnosis there is renewed hope as the market enters a new phase of development.


The KOL Insight module of Alzheimer’s Disease: Beta-amyloid light fases to leave development hole is compiled from exclusive, in-depth interviews with the world’s leading KOLs in AD. It identifies and analyses the major factors, advances and trends currently influencing the AD treatment landscape. The report focuses on late-stage pipeline products, and how these could modify future AD management.


FirstWord selected the KOLs for this Therapy Trends report based on their level of engagement and influence within the AD pharmaceutical industry, and their scientific standing. Our unique KOL scoring system identifies those thought-leaders with the greatest insight into how AD clinical research will shape the future market.


Scope


Key Benefits


Alzheimer’s disease: Beta-amyloid light fades to leave development hole examines the most prominent insights gained from the field’s key opinion leaders. The results of FirstWord’s research and analysis will help you to:


  • •Comprehend the current trends driving and shaping the global AD market

  • •Understand the future landscape and how new classes will fit into the treatment algorithm

  • •Assess the commercial and clinical potential of the pipeline beta-amyloid and BACE inhibitors

  • •Develop planning strategies based from KOL insight

  • •Identify the unmet needs and opportunities for disease management

  • •Evaluate the performance of companies with the most robust new product pipelines

  • •Recognise the key factors KOLs predict will drive future treatment trends

  • Highlights


    Alzheimer’s disease: Beta-amyloid light fades to leave development hole answers key questions including:


    •What do KOLs make of the sola and bapi failures?


  • •What are the current unmet needs and major challenges in AD treatment?

  • •What are the most promising late-stage classes in development?

  • •Which therapy are KOLs eagerly awaiting?

  • •How will the beta-amyloid and BACE inhibitors be positioned in the AD market?

  • •In what ways could eventual biomarkers improve future AD disease management?

  • •How will treatment of AD look in the future?

  • •How do KOLs think the pricing environment will shape the uptake of new AD treatments?

  • •What clinical research trends do KOLs predict for future AD therapies?

  • Puchase Reasons


    Alzheimer’s Disease Panel of Key Opinion Leaders


    FirstWord selected the KOLs for this Therapy Trends report based on their level of engagement and influence within the AD pharmaceutical industry, and their scientific standing. The AD panel assembled for this Therapy Trends research is drawn from North America and Europe professionals:


  • •Assistant Professor at Department of Neurology and Neurological Sciences, Stanford, California, USA

  • •Chief Medical/Scientific Officer of Sun Health Research Institute, Sun City, Arizona, USA

  • •Assistant Professor of Neurosciences at the University of California, San Diego, USA

  • •Professor at Columbia University Medical Center in the Departments of Psychiatry, Neurology, and Pharmacology, New York, USA

  • •Professor of Psychiatry, Neurology, and Gerontology at the Keck School of Medicine of the University of Southern California, California, USA

  • •Associate Professor of clinical neurology and neuroscience at New York Presbyterian Hospital and Weill Cornell Medical College, New York, USA

  • •Adjunct Assistant Professor, Department of Neurology, UCLA, Los Angeles, USA

  • •Head of the department in Geriatric Psychiatry at the University of Heidelberg, Heidelberg, Germany

  • •Neurologist, Department of Clinical Neurosciences at University of Cambridge, Cambridge, UK

  • •Director, CNS Research at Chiesi Farmaceutici, Milan, Italy

  • •Neurologist at Karolinska Institutet, Stockholm, Sweden


  • Event Assessments


    Stay a step ahead with Therapy Trends Event Assessments. Over the next 12 months, you will receive updated qualitative analysis each time a major market event breaks. Updates will be delivered straight into your inbox within days of each event’s occurrence.


    Whether it’s a predicted product approval or an unexpected late stage failure, Therapy Trends has the resources and knowledge to keep you up to date with the latest market analysis.


    Methodology


    This report provides a qualitative overview of the current and future Alzheimer’s disease (AD) market. Information was gathered from telephone discussions held with twelve key opinion leaders (KOLs), from across the major AD markets, including France, Germany, Italy, the UK and the US. These regions were selected because they contain many of the largest global markets for the pharmaceutical industry, and also dictate the dynamics of Pharma markets in other countries.


    In order to critically select Key Opinion Leaders (KOLs) a number of parameters were considered including their clinical experience, scientific publications, involvement with Pharma, involvement in clinical trials, and record of presenting at high profile international conferences.


    Subject matter for discussion in the interviews covered future diagnostic and therapeutic strategies for AD, the future of AD drug classes, and new drugs entering the market. These leading KOLs also gave their views on current research, the usefulness of existing AD drug classes, the cost of newer drugs and other concerns in the therapy area.

    Table of Contents
    for Therapy Trends: Alzheimer's Disease - Breaking new ground in disease modification [Published by FirstWord Pharma]

    • 1.Current Alzheimer’s disease marketplace

      2.Current treatment landscape

      3.Reimbursement of key Alzheimer’s disease brands

      4.Current therapies

      5.Aricept (donepezil; Eiasi/Pfizer) trends

      6.Exelon (rivastigmine; Novartis) trends

      7.Razadyne (galantamine; Johnson & Johnson/Shire) trends

      8.Namenda/Ebixa (memantine; Forest/Merz/Lundbeck) trends

      9.Current treatment algorithm

      10.Unmet needs in Alzheimer’s disease

      11.Pipeline Alzheimer’s disease therapies

      12.Beta-amyloid overview

      13.Solanezumab (LY2062430, Eli Lilly) trends

      14.Gammagard (immune globulin IV [human], Baxter) trends

      15.Gantenerumab (Roche) trends

      16.Bapineuzumab (Johnson & Johnson/Pfizer) trends

      17.BACE inhibitor overview

      18.MK-8931 (Merck) trends

      19.Future prescribing trends

      20.Future developments in Alzheimer’s disease

      21.Clear definition of disease-modifying is required

      22.Improved understanding of underlying disease etiology

      23.Therapies targeting tau

      24.Gene therapy as a treatment option

      25.Enrolment of trials will be more important for success

      26.Identification of patients earlier in disease course for intervention

      27.Development of biomarkers will aid diagnosis and treatment

    Additional Details

    Publisher

    FirstWord Pharma

    Publisher Information

    Reference

    16 |

    Number of Pages

    162

    Report Format

    PDF

    FirstWord Pharma Reports

    Related Reports

    TitleDate PublishedPrice fromMore Details
    Global Gene Therapy Partnering Terms and Agreements 2010 to 2016
    The Global Gene Therapy Partnering Agreements 2010-2016 report provides an understanding and access ...
    01 Oct 2016 by Current Partnering USD $2,995 More Info
    Pathfinder Cell Therapy, Inc. (PFND) - Financial and Strategic SWOT Analysis Review
    SummaryPathfinder Cell Therapy, Inc. (Pathfinder) is a regenerative medicine company that develops n...
    08 Nov 2015 by Global Data USD $300 More Info
    Wright Therapy Products - Medical Equipment - Deals and Alliances Profile
    SummaryWright Therapy Products (Wright) is a medical device manufacturing company that provides pneu...
    03 Nov 2015 by Global Data USD $250 More Info
    Physician Views: What scope for the next oral RA therapy?
    Scope The rheumatoid arthritis (RA) market is one of the largest in the pharmaceutical sector and is...
    01 Apr 2015 by FirstWord Pharma USD $695 More Info
    Physician Views: How comfortable are doctors with the commercial use of gene therapy?
    Scope Gene therapy has been around for decades, yet in a sense the concept has recently been made to...
    23 Mar 2015 by FirstWord Pharma USD $695 More Info
    Physician Views – Defining a suitable NASH therapy
    Scope Excitement around the opportunity for therapies that are designed to treat nonalcoholic steato...
    04 Mar 2015 by FirstWord Pharma USD $695 More Info
    Physician Views: Sanofi's Lemtrada finally approved in the US – how will neurologists use the multiple sclerosis therapy?
    Scope Two years after it was first submitted for approval with the FDA, Sanofi's multiple sclerosis ...
    25 Nov 2014 by FirstWord Pharma USD $695 More Info
    Physician Views: Avastin to lose share as front-line therapy for first-line metastatic colorectal cancer?
    Scope Two recent developments appear poised to shift the typical US-based treatment regimen for firs...
    13 Jul 2014 by FirstWord Pharma USD $695 More Info
    Physician Views: Are neurologists ready to embrace gene therapy?
    Scope As recently noted by Forbes, the biotech bull market of 2013 has helped to revive an approach ...
    11 Jun 2014 by FirstWord Pharma USD $695 More Info
    Physician Views: What opportunity for Gilead Sciences' hepatitis C therapy sofosbuvir before interferon-sparing regiments reach the market?
    ScopeOne of the key features of the hepatitis C treatment landscape over the past year to 18 months ...
    01 Oct 2013 by FirstWord Pharma USD $695 More Info

    This report is published by FirstWord Pharma

    Download Free Report Summary PDF

    Therapy Trends: Alzheimer's Disease - Breaking new ground in disease modification [Published by FirstWord Pharma] | Download PDF Summary

    Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

    Ordering Information

    Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

    Accepted Card Types

    Payment

    Buy now using our secure payment system.

    We Stock...